EpidStrategies A Division of ToxStrategies Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • EpidStrategies A Division of ToxStrategies's estimated annual revenue is currently $22.7M per year.(i)
  • EpidStrategies A Division of ToxStrategies's estimated revenue per employee is $255,202

Employee Data

  • EpidStrategies A Division of ToxStrategies has 89 Employees.(i)
  • EpidStrategies A Division of ToxStrategies grew their employee count by -4% last year.

EpidStrategies A Division of ToxStrategies's People

NameTitleEmail/Phone
1
Senior Statistician IIReveal Email/Phone
2
Senior ConsultantReveal Email/Phone
3
Senior EpidemiologistReveal Email/Phone
4
Supervising EpidemiologistReveal Email/Phone
5
Supervising StatisticianReveal Email/Phone
6
Senior Epidemiologist IIReveal Email/Phone
7
Epidemiologist IIIReveal Email/Phone
8
Senior EpidemiologistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M26-10%N/AN/A
#2
N/A110%N/AN/A
#3
$7.2M28-7%N/AN/A
#4
$10.5M24-44%N/AN/A
#5
$344.1M166718%N/AN/A
#6
$27.5M1239%N/AN/A
#7
$107.3M52419%N/AN/A
#8
$12.9M6428%N/AN/A
#9
$31.6M1454%N/AN/A
#10
$31.4M125-3%N/AN/A
Add Company

What Is EpidStrategies A Division of ToxStrategies?

EpidStrategies is founded on rigorous scientific principles that guide our research on complex health conditions. With a focus on pharmaceuticals, medical devices, and environmental chemicals, our scientists aid clients in the conduct, evaluation, and interpretation of epidemiological studies. Our research frequently results in peer-reviewed publications and presentations at scientific conferences, as well as being used in numerous regulatory documents in the US and Europe.

keywords:N/A

N/A

Total Funding

89

Number of Employees

$22.7M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.3M891%N/A
#2
$12.5M89-39%$30M
#3
$22M90-1%N/A
#4
$15M900%N/A
#5
$36M9011%N/A